SGLT2 Inhibitors May Reduce Blood Pressure in Type 2 Diabetes
Sodium-glucose cotransporter 2 inhibitors reduced both systolic and diastolic blood pressure in patients with type 2 diabetes.
All articles by Waseem Qureshi
Liraglutide, Metformin, and Gliclazide Compared in Comorbid Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
Liraglutide and metformin yielded higher reductions in HbA1c levels when compared with gliclazide.
USPSTF Updates Recommendations for Screening Obesity in Children and Adolescents
Updates to the US Preventive Services Task Force’s recommendations on obesity screening in children and adolescents focus on intensive behavioral interventions.
Semaglutide Improved Beta-Cell Function and Glycemic Control in Type 2 Diabetes
Semaglutide significantly increased insulin response and was well-tolerated in patients with type 2 diabetes.
Blood Glucose Self-Monitoring in Type 2 Diabetes Does Not Benefit Glycemic Control
There were no significant differences in hemoglobin A1c across the 3 self-monitoring blood glucose groups.
Device-Supported vs Routine Titration in Type 2 Diabetes
More patients in the device-supported group achieved a fasting self-monitored plasma glucose target of 90 to 130 mg/dL at week 16 without severe hypoglycemia.
Transition-of-Care Algorithm Performs Well in Surgery Patients With Type 2 Diabetes
HbA1c fell from 7.9%±2.0% at admission to 7.1%±1.5% at 3 months after discharge.
Ezetimibe Reduces LDL-C, Colesevelam Reduces HbA1c in Type 2 Diabetes
At 3 months, ezetimibe produced greater reductions in LDL cholesterol, whereas colesevelam produced greater reductions in HbA1c levels.
Long-Term Testosterone Treatment Reduced HbA1c in Men With Hypogonadism and Type 2 Diabetes
At 12 years of testosterone treatment, HbA1c decreased to 5.5±0.3%.
Nerve Decompression Potentially Beneficial in Painful Diabetic Neuropathy
Researchers assessed whether neurolysis could alleviate pain associated with diabetic neuropathy.
- Loading...
Loading...
Next post in ADA 77th Scientific Sessions 2017
Loading... 
Loading...